Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardonilizumab plus induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced high‑risk cervical cancer
ChiCTR2400094733Phase 2Recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Cervical Cancer (CC), sponsored by The First Hospital of Lanzhou University. Primary endpoint: Progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400094733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094733.